Okogen Inc

Okogen Inc. is a clinical stage ophthalmic pharmaceutical company focused on innovating treatments for Acute Infectious Conjunctivitis, also known as pink eye. Their lead product is currently in Phase 2B clinical trials and aims to provide a comprehensive solution for all forms of this condition, which can be caused by bacterial and viral infections.

The company highlights the significant market opportunity in the conjunctivitis sector, valued at $4.2 billion annually and projected to grow substantially. With the majority of treatments currently relying on antibiotics, Okogen is dedicated to addressing the unmet needs for effective therapies, particularly for adenoviral conjunctivitis, which accounts for 90% of viral ocular infections.

Generated from the website